A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

David R. Wise, Russell K. Pachynski, Samuel R. Denmeade, Rahul R. Aggarwal, Jiehui Deng, Victor Adorno Febles, Arjun V. Balar, Minas P. Economides, Cynthia Loomis, Shanmugapriya Selvaraj, Michael Haas, Michael H. Kagey, Walter Newman, Jason Baum, Andrea B. Troxel, Sarah Griglun, Dayna Leis, Nina Yang, Viktoriya Aranchiy, Sabrina MachadoErika Waalkes, Gabrielle Gargano, Nadia Soamchand, Amrutesh Puranik, Pratip Chattopadhyay, Ezeddin Fedal, Fang Ming Deng, Qinghu Ren, Luis Chiriboga, Jonathan Melamed, Cynthia A. Sirard, Kwok Kin Wong

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)'. Together they form a unique fingerprint.

Medicine & Life Sciences